Can Levofloxacin Cause LFT Elevation?
Yes, levofloxacin can cause liver function test elevations, ranging from asymptomatic transaminase increases to severe, potentially fatal hepatotoxicity, though this adverse effect is uncommon.
Incidence and Clinical Significance
Levofloxacin-induced hepatotoxicity is well-documented but relatively rare. The FDA drug label explicitly states that severe hepatotoxicity, including acute hepatitis and fatal events, has been reported in patients taking levofloxacin 1. Recent retrospective analyses confirm this risk, with one study identifying male sex, elevated C-reactive protein, and high hemoglobin levels as risk factors for drug-induced liver injury (DILI) with levofloxacin 2.
The clinical spectrum is broad:
- Asymptomatic transaminase elevations (most common presentation)
- Symptomatic hepatitis with jaundice, nausea, vomiting, and abdominal pain
- Fulminant hepatic failure requiring transplantation or resulting in death 3, 4
Pattern of Liver Injury
Levofloxacin-induced liver injury presents in multiple patterns 3:
- Hepatocellular pattern (62.5% of cases) - predominant elevation of ALT/AST
- Mixed pattern (25% of cases) - combined hepatocellular and cholestatic features
- Cholestatic pattern (12.5% of cases) - predominant elevation of alkaline phosphatase and bilirubin
The median time to onset is 5 days (range 1-199 days), though delayed presentations can occur 3. This relatively rapid onset distinguishes it from some other antibiotic-related hepatotoxicity.
Clinical Manifestations and Monitoring
Patients should be instructed to immediately discontinue levofloxacin and contact their physician if they develop signs of liver injury, including 1:
- Loss of appetite
- Nausea or vomiting
- Fever, weakness, or tiredness
- Right upper quadrant tenderness
- Itching
- Yellowing of skin and eyes (jaundice)
- Light-colored bowel movements or dark urine
The FDA label emphasizes that severe and sometimes fatal cases of hepatotoxicity have been reported postmarketing, with the majority of fatal cases occurring in patients ≥65 years of age 1. Most fatal cases were not associated with hypersensitivity reactions.
Management Approach
Immediate discontinuation of levofloxacin is warranted if there is rapid increase in aminotransferase levels or emergence of hepatitis symptoms 3. The management algorithm should include:
Stop levofloxacin immediately if AST/ALT >3× upper limit of normal with symptoms, or >5× upper limit of normal without symptoms (applying general DILI principles from tuberculosis guidelines) 5
Evaluate for alternative causes: Perform serologic testing for viral hepatitis (A, B, C) and assess for other hepatotoxins, particularly alcohol 5
Monitor recovery: After discontinuation, the median time to normalization of liver function is 21 days (range 3-103 days) 3
Consider alternative antibiotics: Do not rechallenge with levofloxacin or other fluoroquinolones given cross-reactivity potential
Risk Factors
Clinicians should exercise heightened caution when prescribing levofloxacin to patients with 2:
- Male sex (OR 6.975)
- Elevated baseline C-reactive protein (OR 1.182 per unit increase)
- High hemoglobin levels (OR 1.640)
- Age ≥65 years 1
- Pre-existing liver disease (though pharmacokinetics are not significantly altered) 1
Context Among Antibiotics
Antibiotics are the most common cause of drug-induced liver injury across major studies 6. In one institutional analysis, antibiotics accounted for 64% of DILI consultations, with fluoroquinolones being among the frequently implicated agents 7. The prevalence of antibiotic-associated DILI ranges from 2-14% depending on the specific agent 7.
Clinical Pitfalls
- Do not assume safety based on short treatment duration: Cases have occurred after single doses 4, 8
- Do not overlook delayed presentations: While median onset is 5 days, cases can present weeks after exposure
- Do not continue therapy with minor LFT elevations in high-risk patients: The progression to fulminant hepatitis can be rapid
- Do not rechallenge: Unlike some tuberculosis medications where sequential reintroduction is attempted 5, levofloxacin should not be restarted after hepatotoxicity
Close monitoring of liver function tests is essential when levofloxacin is administered, particularly in elderly male patients with inflammatory markers or comorbidities 2. Alternative antibiotics should be strongly considered in patients with identified risk factors.